Will Korean bio stocks rebound as MSCI includes Celltrion, Viromed, HLB?
기사승인 2018.05.16 11:25:14
Marian Chu yjc@docdocdoc.co.kr
- 1Pharma5 Korean biopharmaceuticals most active in P3 trials in 5 years
- 2Bio‘Pharmaceutical stocks to bottom out soon’
- 3Policy‘Law should protect Good Samaritan doctors’
- 4PharmaShire’s hereditary angioedema therapy gets insurance coverage
- 5HospitalMajor hospitals successfully contain Korea’s 1st MERS case in 3 years
- 6PharmaForeign CEOs to lead Korean units of Novartis, Galderma
- 7PharmaSanofi Pasteur, KSOC vaccinate S. Korean national squad for 2018 Asian Games
set_C1
